<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895553</url>
  </required_header>
  <id_info>
    <org_study_id>ABTCv2-2102</org_study_id>
    <secondary_id>IRB00242129</secondary_id>
    <secondary_id>J2026</secondary_id>
    <nct_id>NCT04895553</nct_id>
  </id_info>
  <brief_title>Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban</brief_title>
  <official_title>Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioma patients with history of venous thromboembolism (VTE) treated on low molecular weight&#xD;
      heparin (LMWH) and who decided with their physician to convert to Apixaban (oral drug) will&#xD;
      be enrolled into our study and will collect data regarding recurrent VTE and Intracranial&#xD;
      hemorrhage and the incidence of these events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives To estimate the incidence of intracranial hemorrhage (ICH) in glioma&#xD;
      patients with history of venous thromboembolism (VTE) after the conversion from low molecular&#xD;
      weight heparin (LMWH) injections to oral Apixaban.&#xD;
&#xD;
      Secondary Objective To estimate the incidence of recurrent VTE in glioma patients with&#xD;
      history of venous thromboembolism after the conversion from low molecular weight heparin&#xD;
      (LMWH) injections to oral Apixaban.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial Hemorrhage (ICH) event incidence rate</measure>
    <time_frame>1 year</time_frame>
    <description>Observe subject to determine the incidence of ICH during standard of care (SOC) observations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deep venous thromboembolism (VTE) event incidence rate</measure>
    <time_frame>1 year</time_frame>
    <description>Observe subject to determine the incidence of VTE during SOC observations.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glioma, Malignant</condition>
  <arm_group>
    <arm_group_label>Cohort Apixaban</arm_group_label>
    <description>patients who have switched from low molecular weight heparin (LMWH) to apixaban at the recommended dose of the treating physician.&#xD;
FDA approved dose 10 mg twice daily (BID) for 7 days followed by 5 mg PO BID OR physician prescribed dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation of ICH and VTE</intervention_name>
    <description>The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.</description>
    <arm_group_label>Cohort Apixaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients greater than or equal to 18 years of age who have had a pathologically confirmed&#xD;
        supra-tentorial primary brain tumor and a history of deep venous thrombosis (DVT) and/or&#xD;
        pulmonary embolism (PE).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be 18 years of age or older;&#xD;
&#xD;
          -  Patients must have had a pathologically confirmed supra-tentorial primary brain tumor&#xD;
&#xD;
          -  Patients must have history of deep venous thrombosis (DVT) and/or pulmonary embolism&#xD;
             (PE)&#xD;
&#xD;
          -  Patients must have been treated with low molecule weight heparin for â‰¥ 5 days&#xD;
&#xD;
          -  Patients must be able to provide written informed consent&#xD;
&#xD;
          -  Patients must have non contrast CT that is negative for intra-cranial bleed at least 5&#xD;
             days post initiation of LMWH and prior to initiation (within 7 days) of Apixaban&#xD;
&#xD;
          -  Must be decision by patient and his physician to convert to Apixaban&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a plan less than 6 months of anticoagulation for most recent DVT or PE&#xD;
&#xD;
          -  Patients with allergic reaction to Apixaban&#xD;
&#xD;
          -  Patients with active bleeding or high risk for bleeding contraindicating treatment&#xD;
             with LMWH&#xD;
&#xD;
          -  Patients with planned surgery in the next 2 weeks&#xD;
&#xD;
          -  Patients previously treated with Apixaban&#xD;
&#xD;
          -  Patients requiring Acetylsalicylic Acid (ASA) greater than165 mg/day at enrollment&#xD;
&#xD;
          -  Patients requiring dual anti-platelet therapy (ASA plus clopidogrel or ASA plus&#xD;
             ticlopidine) at enrollment.&#xD;
&#xD;
          -  Subjects with transition for dual anti-platelet therapy or monotherapy prior to&#xD;
             enrollment will be eligible for the study&#xD;
&#xD;
          -  Patients who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (e.g. infectious disease) illness&#xD;
&#xD;
          -  Any condition, which in the opinion of the investigator, would put the subject at an&#xD;
             unacceptable risk from participating in the study&#xD;
&#xD;
          -  Any other medical, social, logistical, or psychological reason, which in the opinion&#xD;
             of the investigator, would preclude compliance with, or successful completion of, the&#xD;
             study protocol&#xD;
&#xD;
          -  Known active and clinically significant liver disease (e.g., hepatorenal syndrome)&#xD;
&#xD;
          -  Known bacterial endocarditis&#xD;
&#xD;
          -  Know uncontrolled hypertension: systolic blood pressure greater than 160 mm Hg or&#xD;
             diastolic blood pressure greater than 100 mm Hg; (subjects who have a transient,&#xD;
             higher blood pressure elevation associated with acute PE [upper limit: systolic blood&#xD;
             pressure 200 mm Hg or diastolic blood pressure 100 mm Hg] may enter the study;)&#xD;
             elevated blood pressure that is persistent 1 - 2 days after the index DVT or PE should&#xD;
             be treated according to local guidelines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart A Grossman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joy D Fisher, MA</last_name>
    <phone>410-955-8837</phone>
    <email>jfisher@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stuart A Grossman, MD</last_name>
    <phone>410-955-8837</phone>
    <email>grossman@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Orwa Aboud, MD</last_name>
      <phone>916-734-6788</phone>
      <email>oaboud@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Orwa Aboud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michealla Iacoboni, RN</last_name>
      <phone>410-955-8837</phone>
      <email>msheeh13@jh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Dobson-Brown, BS</last_name>
      <phone>410-955-8837</phone>
      <email>tdobson1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stuart A Grossman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apixaban</keyword>
  <keyword>Glioma</keyword>
  <keyword>ICH</keyword>
  <keyword>DVT</keyword>
  <keyword>LMWH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

